Denis Chetverikov appointed as the new president of AKRIKHIN

10.04.2014

AKRIKHIN Board of Directors decided to appoint Denis Chetverikov as the new President of the Management Board as of May 1.

As a result of the resignation submitted for personal reasons by Jan Slob, the current President of AKRIKHIN, the Board of Directors appointed Denis Chetverikov as the new President of the company.

Denis Chetverikov, who will assume the position of the President as of May 1, has nearly 20 years of experience in the Russian pharmaceutical market. A physician by education, he has worked as the General Manager at Teva (and IVAX) in Russia for the last 10 years. Previously, he had held various positions in marketing and sales at Abbott and Roche.

I am glad that I can join the AKRIKHIN team. The company is growing faster than the local pharmaceutical market. My goal as the president will be to strengthen the company’s position and improve all its business indices”, said Denis Chetverikov.

Jan Slob has managed AKRIKHIN since 2007. During that period he significantly improved the performance of the company, contributed to building the position of AKRIKHIN as one of the leading Russian pharmaceutical companies and to its development under the government program “Strategy of pharmaceutical industry development in

the Russian Federation for the period up to the year 2020” («PHARMA 2020»).

ABOUT AKRIKHIN

AKRIKHIN is one of the leading Russian pharmaceutical companies. It manufactures effective, high-quality medicines at affordable prices. In terms of sales value, it is one of the top ten biggest local drug manufacturers in the Russian market.


AKRIKHIN was established in 1936. It offers over 200 products (over 100 brands) used primarily in such therapeutic areas as cardiology, neurology, paediatrics, gynaecology, dermatology, urology and ophthalmology. AKRIKHIN manufactures a wide range of socially important drugs and it is one of the largest Russian manufacturers of
Essential Drugs, as well as drugs for diabetes and tuberculosis treatment.

In 2013, AKRIKHIN ranked 3rd in the Rating of influence of Russian pharmaceutical market participants (according to the “Pharmatsevticheskiy vestnik”).

Media contact:

Akrikhin Company: Yulia Zaika, j.zaika@akrikhin.ru, contact phone: +7 916 839 95 71,

www.akrikhin.ru


We use cookies to improve your experience on our site and to show you personalised advertising. By pressing “I AGREE” you accept our cookies policy.
To find out more, go to cookies policy.
I AGREE